LabGenomics Acquires Kels, an In Vitro Diagnostic Company, Shares Worth 2 Billion KRW
[Asia Economy Reporter Minwoo Lee] LabGenomics announced on the 1st that it has decided to acquire 134,680 shares of Kels, a research and development company of in vitro diagnostic devices, worth approximately 2 billion KRW. The company explained, "This is a strategic investment to establish growth momentum through business diversification and to supply immune diagnostic kits."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "Reporters Who First Revealed Jo Jinwoong's Juvenile Offense History Cleared of Juvenile Act Violation"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
